ATE228362T1 - Verwendung eines retinoidids zur in vivo erhöhung der entkopplung des ucp2 proteins - Google Patents

Verwendung eines retinoidids zur in vivo erhöhung der entkopplung des ucp2 proteins

Info

Publication number
ATE228362T1
ATE228362T1 AT98936435T AT98936435T ATE228362T1 AT E228362 T1 ATE228362 T1 AT E228362T1 AT 98936435 T AT98936435 T AT 98936435T AT 98936435 T AT98936435 T AT 98936435T AT E228362 T1 ATE228362 T1 AT E228362T1
Authority
AT
Austria
Prior art keywords
vivo
decoupling
retinoidid
activity
increase
Prior art date
Application number
AT98936435T
Other languages
English (en)
Inventor
Frederic Bouillaud
Daniel Ricquier
Zueco Eduardo Rial
Original Assignee
Consejo Superior Investigacion
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior Investigacion, Centre Nat Rech Scient filed Critical Consejo Superior Investigacion
Application granted granted Critical
Publication of ATE228362T1 publication Critical patent/ATE228362T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT98936435T 1997-08-05 1998-08-05 Verwendung eines retinoidids zur in vivo erhöhung der entkopplung des ucp2 proteins ATE228362T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9710009A FR2767058B1 (fr) 1997-08-05 1997-08-05 Utilisation d'un compose de type retinoide, notamment l'acide retinoique pour la preparation d' un medicament destine au traitement de l'obesite.
PCT/ES1998/000225 WO1999007358A1 (es) 1997-08-05 1998-08-05 Utilizacion de un compuesto de tipo retinoide para modular in vivo la actividad desacopladora de la proteina ucp2

Publications (1)

Publication Number Publication Date
ATE228362T1 true ATE228362T1 (de) 2002-12-15

Family

ID=9510039

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98936435T ATE228362T1 (de) 1997-08-05 1998-08-05 Verwendung eines retinoidids zur in vivo erhöhung der entkopplung des ucp2 proteins

Country Status (9)

Country Link
US (2) US20030229143A1 (de)
EP (1) EP1018338B1 (de)
AT (1) ATE228362T1 (de)
AU (1) AU8543098A (de)
CA (1) CA2299270A1 (de)
DE (1) DE69809785T2 (de)
ES (2) ES2147519B1 (de)
FR (1) FR2767058B1 (de)
WO (1) WO1999007358A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576906B1 (en) 1999-10-08 2003-06-10 Symyx Technologies, Inc. Method and apparatus for screening combinatorial libraries for semiconducting properties
AU1763201A (en) * 1999-11-10 2001-06-06 Mitokor Modulation of mitochondrial mass and function for the treatment of diseases and for target and drug discovery
US6365796B1 (en) * 2000-02-16 2002-04-02 Beth Israel Deaconess Medical Center Transgenic UCP2 knockout mouse and use thereof
WO2001075131A2 (en) * 2000-03-31 2001-10-11 University Technology Corporation Expression of uncoupling protein (ucp) in plants
US7105718B2 (en) 2000-03-31 2006-09-12 The Regents Of The University Of Colorado Compositions and methods for regulating metabolism in plants
ES2177404B1 (es) * 2000-07-07 2004-09-16 Consejo Superior De Investigaciones Cientificas Procedimiento para la determinacion de la actividad de las proteinas desacoplantes (ucps) mediante la monitorizacion del consumo de nad (p) h.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5051449A (en) * 1991-02-27 1991-09-24 Kligman Albert M Treatment of cellulite with retinoids
US5219888A (en) * 1992-03-31 1993-06-15 American Cyanamid Company Use of retinoids for the treatment of coronary artery disease
TW272187B (de) * 1992-05-20 1996-03-11 Hoffmann La Roche
US5457129A (en) * 1993-05-17 1995-10-10 Research Development Foundation Inhibition of nitric oxide production by retinoic acid
WO1995018533A1 (en) * 1994-01-04 1995-07-13 The Trustees Of The University Of Pennsylvania Methods and compounds affecting adipocyte differentiation and obesity
FR2723315B1 (fr) * 1994-08-02 1996-10-25 Cird Galderma Procede et composition pour stimuler la differenciation des cellules preadipocytaires et traitements therapeutiques associes
US5489611A (en) * 1995-02-10 1996-02-06 Warner-Lambert Company Method for lowering plasma levels of lipoprotein (a)
FR2735367B1 (fr) * 1995-06-19 1997-07-18 Cird Galderma Utilisation de ligands specifiques des recepteurs rxrs
ES2216062T3 (es) * 1995-09-18 2004-10-16 Ligand Pharmaceuticals, Inc. Tratamiento de la niddm con agonistas del rxr.

Also Published As

Publication number Publication date
CA2299270A1 (en) 1999-02-18
AU8543098A (en) 1999-03-01
FR2767058B1 (fr) 2000-05-05
ES2189213T3 (es) 2003-07-01
DE69809785D1 (de) 2003-01-09
WO1999007358A1 (es) 1999-02-18
EP1018338B1 (de) 2002-11-27
US20030229143A1 (en) 2003-12-11
ES2147519A1 (es) 2000-09-01
US20070015830A1 (en) 2007-01-18
FR2767058A1 (fr) 1999-02-12
ES2147519B1 (es) 2001-03-16
EP1018338A1 (de) 2000-07-12
DE69809785T2 (de) 2003-09-18

Similar Documents

Publication Publication Date Title
PL2157192T3 (pl) Kompozycje do diagnozowania i terapii chorób związanych z nieprawidłową ekspresją futrin (R-spondin)
MX9606404A (es) Composiciones farmaceuticas y metodos para formular trasnduccion de señales.
BR0116803A (pt) Proteìnas de fusão bifuncionais com atividade de glicocerebrosidase
PT93082A (pt) Processo de producao de um derivado de activador de plaminogenio tissular, de plasmideo de expressao e de medicamento contendo o referido derivado
DE69815323D1 (de) Therapeutische nahrung für diabätiker
DE59407237D1 (de) Nitrato-aminosäure-disulfide zur therapie von erkrankungen des herz-kreislauf-systems
DE602007014210D1 (de) Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen
ATE493978T1 (de) Behandlung von autoimmunerkrankungen
DE69836139D1 (de) Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davon
LU93259I2 (fr) LETIFEND (Protein Q)
PT87523A (pt) Mischkristalle aus insulin und insulinderivaten verfahren zur herstellung dieser mischkristalle diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
EA199700380A1 (ru) Бициклические ароматические соединения, фармацевтическая и косметическая композиции на их основе и применение косметической композиции
DE60142239D1 (de) DEN PHOSPHORSÄURE-METABOLISMUS, DEN KALZIUM-METABOLISMUS, VERKALKUNG UND DEN VITAMIN D-METABOLISMUS KONTROLLIERENDE POLYPEPTIDE SOWIE FüR DIESE KODIERENDE DNA-MOLEKÜLE
ATE82127T1 (de) N-acetylglucosamin-zubereitungen zur buccalen anwendung.
ATE228362T1 (de) Verwendung eines retinoidids zur in vivo erhöhung der entkopplung des ucp2 proteins
ATE395602T1 (de) Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
BR9804921A (pt) Peptìdeo natriurético atrial (anp) como um aditivo para soluções de diálise peritoneal.
DE60107888D1 (de) Beta-Interferon zur Behandlung von Immunerkrankungen
DE69837148D1 (de) Chimäre proteine zur behandlung von diabetes
DE60118769D1 (de) Verwendung von langem pentraxin ptx3 zur behanlung von durch geänderte aktivität des fgf-2 wachstumsfaktors hervorgerufene krankheiten
ITRM920506A1 (it) Regioni antigeniche dei complessi tpl e anticorpi diretti contro di essi.
DE58906606D1 (de) Optisch aktive Rhodiumkomplexe von 3,4-Bis(diarylphosphino)-pyrrolidinen und ihre Verwendung zur Herstellung von Phosphinothricin durch asymmetrische Hydrierung.
ATE317021T1 (de) Antisense modulierung von lfa-3
EE05139B1 (et) Peptiid, seda kodeeriv geen, reagent ja reaktiivikomplekt riketsioosi tuvastamiseks ning peptiidi sisaldav vaktsiin
ATE308984T1 (de) Arzneiformen zur behandlung von krankheiten, die auf aktivierung des ppar-gamma-rezeptors ansprechen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties